scorpion
- 13 Aug 2003 13:54
Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.
Big Al
- 03 Jun 2005 10:24
- 1989 of 2372
Glad my dosh isn't with that "institutional investor". ;-))
Must be why I do my own stuff now! LOL
ateeq180
- 04 Jun 2005 23:44
- 1990 of 2372
When is the agm,if any one can let us know.Thanks
Dil
- 04 Jun 2005 23:59
- 1991 of 2372
Dunno , when's the 13th next fall on a Friday ?
devmewsman
- 07 Jun 2005 11:05
- 1992 of 2372
BioProgress PLC
07 June 2005
Press Release 7 June 2005
BioProgress plc
('BioProgress' or 'the Company')
Update on partnership developments
BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery
mechanisms for the pharmaceutical oral dosage markets, today announces a
progress update on partnership developments.
BioProgress is delighted to announce that the first NROBE(TM) machine for powder
encapsulation has been delivered to its strategic partner FMC BioPolymer ('FMC
'), a business unit of the FMC Corporation (NYSE:FMC). This is a significant
step in the development of the technology, leading towards full scale
production. BioProgress will continue its close collaboration with FMC to
maximise the commercial potential of NROBE(TM).
The global market for oral dose forms is worth several billion US$ and NROBE(TM)
presents a unique delivery solution to this market. FMC BioPolymer is a global
leader in the supply of products and services to the pharmaceutical and life
sciences industries.
FMC Corporation (NYSE:FMC) is a diversified chemical company serving
agricultural, industrial and consumer markets globally for more than a century
with innovative solutions, applications and quality products. The company
employs approximately 5,500 people throughout the world. The company divides
its businesses into three segments: Agricultural Products, Speciality Chemicals
and Industrial Chemicals.
BioProgress also advises that the exclusive option agreement with Wyeth will not
be extended. BioProgress will continue to explore opportunities with Wyeth.
However, in relation to the Company's SWOLLO liquid-fill encapsulation
technology, BioProgress will extend this exciting technology to other partners
so as to fully exploit and commercialise its potential.
- Ends -
devmewsman
- 07 Jun 2005 11:08
- 1993 of 2372
BioProgress PLC
07 June 2005
Press Release 7 June 2005
BioProgress plc
('BioProgress' or 'the Company')
Issue of Equity / Redemption of Convertible Bond
BioProgress plc (AIM: BPRG; NASDAQ: BPRG) confirms that 4,285,714 ordinary
shares have been admitted for trading on the Alternative Investment Market
today. As announced on 1 June 2005, these new shares represent part
consideration for the repurchase of the convertible bond issued on 6 October
2004 and redeemed on 1 June 2005.
For further information please refer to the Company's statement of 1 June 2005.
- Ends -
BioProgress plc
www.bioprogress.com
Dan Farrow
dan.farrow@bioprogress.com
Finance Director
Big Al
- 07 Jun 2005 12:45
- 1994 of 2372
Ooops!
;-)
Dil
- 08 Jun 2005 00:26
- 1995 of 2372
Yep my thoughts exactly , 4 million plus about to be dumped.
You buying Al ?
:-)
aimtrader
- 12 Jun 2005 16:29
- 1996 of 2372
i'd rather be out than in!!!
Big Al
- 12 Jun 2005 16:36
- 1997 of 2372
Can't really see a purchase yet, Dil. Still think it'll take time to get all the skeletons out - usually does.
However, there'll be time to go long eventually
;-0
iturama
- 13 Jun 2005 10:34
- 1998 of 2372
RNS Number:4690N
BioProgress PLC
13 June 2005
Press Release 13 June 2005
BioProgress plc
("BioProgress" or "the Company")
Peter Glynn-Jones
The Board of BioProgress plc (AIM: BPRG; NASDAQ: BPRG) regrets to announce the
sudden death of Peter Glynn-Jones, Non-Executive Chairman of the Company
aged 58.
Peter joined the Board as a Non-Executive Chairman in May 2003. He was formerly
a senior executive of SmithKline Beecham Plc, now GlaxoSmithKline Plc, and a
non-executive director of Peter Black Plc until it was taken private.
Speaking on behalf of the Board and employees of BioProgress Plc, Richard
Trevillion, Chief Executive, said:
"We are deeply saddened to learn of Peter's death. As Chairman since 2003 he
played an important role in the growth of the Company. He will be greatly
missed and our thoughts are with his family."
An announcement in relation to a successor to Peter Glynn-Jones will be made in
due course.
Fred1new
- 23 Jun 2005 10:58
- 2000 of 2372
What do the wise men say about the SP movement to-day. Smallish Volume B/s 54/45 larger sized buys than sells, but SP down by 3.5%. Is there a large protected sale going through. I would have read the recent announcement as fair and reasonable. But ?????
Dil
- 26 Jun 2005 01:33
- 2001 of 2372
Still 22p target Fred ... sorry.
Snip
- 26 Jun 2005 08:47
- 2002 of 2372
me singing to Dil:
`it ain`t necessarily so` de dum de dum
short term chart I know but it`s sometimes that kind of stock
macd showing positivity
Fred1new
- 26 Jun 2005 10:00
- 2003 of 2372
Dil I don't think it will dive to 22p but 29-30p is possible, but I think from looking at the indicators and this miserable chart the sp will be up over the next few days and weeks.
hugybear
- 26 Jun 2005 21:25
- 2004 of 2372
Dil
Have you not seen the news and specculation over on ADVFN
FMC and Bioprogress partnership and news did not come out until after mkt hrs on Friday so it will be a level playing field at open
FMC BioPolymer Announces New Name for Oral Dose Technology Unit
PHILADELPHIA, June 21, 2005 - FMC BioPolymer, today announced a new identity for its business unit focused on oral dose technologies. The unit, to be called Magenta Oral Dose Design, is currently developing the NRobe system for powder enrobing, and several alternatives to soft capsule dose forms. FMC BioPolymer is a division of FMC Corporation (NYSE: FMC).
"As we interact more strongly with prospective customers and publish more information, it makes sense for us to have a distinctive and recognizable name and identity." commented Robin Mitchell, Director, New Pharmaceutical Business. "We chose Magenta because it reflects our core values, is ownable and has great potential as a point of difference. Of course, it is the strength and value of our technologies that will really define our presence in the market via the business opportunities they create for us, our partners and our customers. We continue to make good progress towards commercialization of our technologies." More details, including a website, will be made available shortly
ateeq180
- 26 Jun 2005 21:40
- 2005 of 2372
Looks good for monday me think.
Fred1new
- 27 Jun 2005 00:10
- 2006 of 2372
Link for information
http://www.bioprogress.com/html/news/archive/09-11-04.html
http://www.fmcbiopolymer.com/Biopolymer/V2/BIONewsDetail/0,1418,3010,00.html
Looks promising.
Fred1new
- 27 Jun 2005 13:12
- 2007 of 2372
BioProgress PLC
27 June 2005
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Bioprogress plc
2. Name of shareholder having a major interest
FMC and it's direct and indirect subsidiaries and
Fidelity International Limited and it's direct and indirect subsidiaries
3. Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18.
As above
4. Name of the registered holder(s) and, if more than one holder, the number
of shares held by each of them
172,688 Brown Brothers Harriman Lux
3,946,901 Mellon Bank N.A.
5. Number of shares/amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares/amount of stock disposed
831,099
8. Percentage of issued class
Not disclosed
9. Class of security
Ordinary shares of 1p each
10. Date of transaction
Not disclosed
11. Date company informed
27 June 2005
12. Total holding following this notification
4,118,901
13. Total percentage holding of issued class following this notification
3.38%
14. Any additional information
15. Name of contact and telephone number for queries
Georgina Godby, 01354 602186
16. Name and signature of authorised company official responsible for making
this notification.
Georgina Godby, Company Secretary
Date of notification: 27 June 2005
I would have thought this was done a couple of days ago as it hasn't been marked up to-day or effected the price.
***************************
How long is it before they have to notify a deal of this size?
******************************************
Kivver
- 20 Jul 2005 14:03
- 2008 of 2372
When is this company going to announce something which is going to make it money?